MOLECULAR DIAGNOSTICS. AIT Austrian Institute of Technology GmbH Center for Health & Bioresources

Transcription

1 MOLECULAR DIAGNOSTICS AIT Austrian Institute of Technology GmbH Center for Health & Bioresources

2 AIT AUSTRIAN INSTITUTE OF TECHNOLOGY OWNERSHIP STRUCTURE 49,54% FEDERATION OF AUSTRIAN INDUSTRIES 50,46% REPUBLIC OF AUSTRIA (through the Federal Ministry for Transport, Innovation and Technology) EMPLOYEES 143 m EUR TOTAL REVENUES 77 m EUR Contract research revenues (incl. Grants) 45 m EUR bmvit funding 21 m EUR Other operating income, incl. Nuclear Engineering Seibersdorf

3 AIT AUSTRIAN INSTITUTE OF TECHNOLOGY AIT Austrian Institute of Technology AIT Austrian Institute of Technology Seibersdorf Labor GmbH Nuclear Engineering Seibersdorf GmbH Energy Health & Bioresources Digital Safety & Security Vision, Automation & Control Mobility Systems Low-Emission Transport Technology Experience Innovation Systems & Policy

4 FOCUS OF THE CENTERS Energy Health & Bioresources Digital Safety & Security Vision, Automation & Control Sustainable Thermal Energy Systems Electric Energy Systems Sustainable Buildings and Cities Photovoltaic Systems Environmental Resources & Technologies Bioresources Molecular Diagnostics Biomedical Systems Digital Health Information Systems Security & Communication Technologies Visual Surveillance and Insight Smart Sensor Solutions Dependable Systems Engineering Information Management High-Performance Image Processing Autonomous Systems Complex Dynamical Systems Mobility Systems Low-Emission Transport Technology Experience Innovation Systems & Policy Transportation Infrastructure Technologies Dynamic Transportation Systems Electric Drive Technologies Light Metals Technologies Ranshofen Capturing / Measuring Experience Future Interface Paradigms Experience Orientated Thinking Digital Innovation Foresight & Institutional Change Policies for Change

5 MOLECULAR DIAGNOSTICS WHO WE ARE We are a team of 33 scientists and ca. 25 PhD and diploma students and our labs are located in Vienna. We have expertise and background in the areas of biology, biochemistry, bioinformatics, physics, chemistry, electrical engineering

6 MOLECULAR DIAGNOSTICS WHAT WE DO We identify and validate useful biomarkers in minimally or non-invasive body fluids We create point-of care solutions to measure biomarkers in those fluids Together with our clinical and industrial partners we create technical solutions for applied questions We have a special focus on saliva as an absolutely non-invasive sample type that is ideally suited for point-of care measurements

7 OUR TECHNICAL CORE COMPETENCIES Biomarker Development Assay Development Diagnostic Biosensors Non-invasive Diagnostics Systems Integration Point-of-Care Bioinformatics

8 BIOMARKER DEVELOPMENT - EXPERTISE Biomolecules DNA Genotyping DNA-methylation Methylation Genomic Aberrations RNA Gene Expression mirna ncrna Protein auto Auto antibody Antibody profiling Profiling Technologies DNA Microarray whole genome targeted Next Generation Sequencing qpcr Microfluidic qpcr Protein Arrays Peptide Arrays Biostatistics Bioinformatics Software Development Infectious Fibroprolif. Fibroprolif. Breast Cancer Colon Breast Cancer Cancer Lung Lung Cancer Cancer Prostate Leukemias Ca Leukemias Thyroid Cancer Thyroid Ca Disease Diseases Diseases Indications Aim: Improving minimal invasive diagnostics

9 BIOINFORMATICS EXPERTISE AND OVERVIEW Clinical Need Experimental Design Operating Conditions Clinical Data Study Design Genomics Epigenomics Transcriptomics Immunomics Proteomics Molecular Data Domain specific knowledge: NGS Chips HT-qPCR Luminex. Feature Selection and Classification under Operating Conditions (cost structures) On longitudinal data. Meta-analysis Biostatistics Diagnostics Disease model characterisation Whole genome analysis Data integration Meta-analysis Gene Set Enrichment Regulatory networks Hypothesis generation Assay Design Validation Studies Software Design

10 ASSAY DEVELOPMENT - SERVICES FOR IMMUNOLOGICALAND BIOCHEMICAL ASSAYS Assay Development & Validation QC Performance improvement POC adaption Saliva adaption Total assay automation Routine Sample Measurement Available Assay Technologies FI UV FRET HTRF Lance Delfia Luminescence (Flash & Glow) Alpha Screen/Lisa Enzyme kinetics (Seconds to minutes to hours)

11 BIOSENSOR DEVELOPMENT OVERVIEW Sample liquid Biosensor Biological targets Receptor surface Transducer Signal readout & processing Display of results Peptides (e.g. hormones) Proteins (e.g. antibodies, enzymes, hormones) Nucleic acids (DNA, RNA, mrna, mirna) Viruses, cells Current national and international projects: Optical Waveguides Surface plasmon resonance (SPR) Fluorescence White light interferometry Colorimetric (lateral flow devices) COHESION, COLODOR, OCTCHIP, PASSION, PLASMOfab, POCbosens Magnetic Magnetic nanoparticles Micro-nuclear magnetic resonance LAMPION Chemoluminescence Magnetoresistance Electrochemical Amperometry Voltammetry Impedance spectroscopy Mass based Quartz crystal microbalance Surface acoustic waves Cantilevers Greensense, IMPETUS, NUMBAT, PathoPOC, PIONIER

12 SYSTEMS INTEGRATION / POINT OF CARE DEVICES - EXPERTISE AND OVERVIEW Biomarker Major requirements: Assay Develop. Biosensors Rapid analysis <30min Compact systems Automation Bioinformatics / Data processing Total Analysis Systems Fluidic handling & storage Cost-effective analysis 3 topics: Sample preparation Process control & Signal acquisition Sample preparation with electrical fields Miniaturised immunoassays External technology Veterinary diagnostics

13 MAJOR RESEARCH PROGRAMMES - OVERVIEW Biomarker and Assay Development DNA-methylation, mirna and autoantibody biomarkers in blood and saliva (e.g. cancer, diabetes) New technical platforms for peptide based immunomics Pre-analytics of body fluids Blood and saliva based detection of pathogens Bioinformatics Bioinformatic part of many projects in the biomarker area New workflows for data handling from different NGSplatforms with a specific focus on RNAseq Statistic interpretation and evaluation for specific molecular diagnostic questions Biosensors Point-of-Care Optical, magnetical and electrochemical technologies for biosensors Printing technologies for electrode systems in the POC Integration of samples prep and detection technologies into POC solutions for noninvasive diagnostics Funding (e.g.): Ultraplacad (H2020, PHC10) FAPIC (H2020, PHC10) MARA (H2020, Fet-Open) Funding (e.g.): Libida (FFG, Bridge) Druid (ZIT) CBMed (FFG, K1 Center) Funding (e.g.): Diagoras (H2020, PHC10) OCTchip (H2020, ICT27) PlasmoFAB (H2020, ICT27)

14 OUR PATENT PORTFOLIO Currently we actively pursue and market the following 17 patent families: Breast cancer autoantibody biomarker Colon cancer autoantibody biomarker Lung cancer autoantibody biomarker Prostate cancer autoantibody biomarker Lung cancer DNA-methylation biomarker Breast cancer DNA-methylation biomarker Colon cancer DNA-methylation biomarker Thyroid cancer DNA-methylation biomarker Thyroid cancer m-rna expression biomarker Rotating nanowires surface plasmon detection technology Cellmonitor wireless signal transfer technology New DNA probe assay technology Microfluid detection system for bed-side molecular diagnosis Selective electrical cell lysis systems New molecular diagnostic technologies (MARA, 3 patent families)

15 OUR TECHNOLOGY MODULE APPROACH In our cooperative as well as in our industry projects we usually act as a provider of technology modules, by e.g. Integrating customers biomarker content onto our own POC platforms Contributing our own content to existing platforms of customers Identifying and developing the ideal sensor solution for partners Contributing our bioinformatics expertise for evaluation of large datasets Integrating all components into complete POC systems In selected projects we are also developing completely new and revolutionary diagnostic technology modules (e.g. H2020 FET-Open project MARA)

16 OUR LABORATORIES INFRASTRUCTURE Molecular Biology Laboratories Modern Molecular Biology Laboratories S2 Laboratory PCR Laboratory Microarray Printing High Throughput Systems (e.g. NGS) Chemistry Laboratory Physics Laboratory Clean Room and CTFT (Center of Thin Film Technology) Magnetron Sputtering Materials Inkjet Printer Optical lithography Atomic Force Microscopy

17 OUR PARTNERS Some Major Academic Partners Some Major Industry Partners Medical University Vienna Vetmed University Vienna Abcodia Infineon UCLA ams Queensland University of Technology Hahn Schickard Gesellschaft (HSG) Joanneum Research Weiz NXT-Dx Platomics Boehringer Ingelheim

18 AIT AUSTRIAN INSTITUTE OF TECHNOLOGY your ingenious partner Dr. Martin Jung Head of Competence Unit Molecular Diagnostics Center for Health & Bioresources